cancer-therapy-and-biomarkers-2016_tracks-abstracts

9 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 31
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Association between levels of 5-hydroxymethylcytosine and clinical/histopathologic features in
locally advanced breast cancer: Results from the biomarkers breast cancer cohort of Mexican
women (2012-2015)
Diddier Prada, Omar Peña Curiel, José Díaz Chávez, Cynthia Villarreal Garza, Nancy Reynoso, Paula Cabrebra Galeana, Enrique Bargalló Rocha,
Yolanda Villaseñor Navarro, Claudia Caro Sánchez, Luis A Herrera, Ramirez-Otero, Miguel, Justo and Montserrat
Instituto Nacional de Cancerología, Mexico
Breast cancer is a leading cause of cancer death in the world. In developing countries, most patients are still diagnosed in
locally advanced stages (LABC), which highlight the importance of identifying prognostic and predictive biomarkers. In
this study, we determined the level of 5-hydroxymethylation (5hmC) in the biopsy at diagnosis. Then, we determined its asso-
ciation with clinical and histopathologic characteristics in a prospective cohort of LABC patients (N=84), diagnosed between
2012 and 2015; using a semi-quantitative enzyme-linked immunosorbent assay. We found a statistically significant association
between low 5hmC levels with histological grade: Mean %5hmC in low grade tumors 0.17%, (95% CI 0.07-0.26%), intermedi-
ate-grade tumors 0.15% (95% CI 0.10-0.19%), high grade tumors 0.066% (95% CI 0.05-0.08%; p<0.001). We also observed an
association between 5hmC levels with histological type: Invasive ductal carcinoma 0.10% (95% CI 0.07-0.12%) vs. non-ductal
invasive carcinoma 0.22% (95% CI 0.07-0.36; p=0.008). Additionally, we found a negative and significant association with
Ki67 (β=-0.012, standard error [SE]=0.0061, p=0.047), a known marker for cellular proliferation. Multivariate analysis con-
firmed the association between lower levels of 5hmC with age (β=-0.066, SE=0.031, p=0.036) and histological grade (β=-1.197,
SE=0.589, p=0.042). No association was observed with therapeutic response or free-relapse survival, probably attributed to
only 2-3 years of follow-up, and to few deaths (N=2) and relapse (N=7) that have been observed. This is the first report on the
association between levels of 5hmC with the histological type and histopathologic grade in a prospective cohort of LABC. Our
findings suggest that 5hmC levels may be a potential biomarker for tumor aggressiveness in LABC.
Biography
Diddier Prada graduated as Medical Doctor from the Universidad Industrial de Santander, Colombia. Then, he pursued a PhD in Biomedical Science at the
Universidad Nacional Autónoma de México (UNAM). He was a Post-doctoral Fellow at Harvard T.H. Chan School of Public Health, from 2013 to 2016; his stay
included one-year and a half as Research Associate in the laboratory of Environmental Epigenetics in the Department of Environmental Health. He is currently
working as Associate Researcher at the National Cancer Institute of Mexico, and he is also Associate Professor of Biomedical Informatics in the Faculty of
Medicine at the UNAM. He has published papers in highly reputed peer-reviewed journals (e.g. Circulation, Environmental Research, and Environmental Health
Perspectives). He has also published one book and five chapters in internationally recognized books, plus one that is currently in press
Diddier Prada et al., Oncol Cancer Case Rep 2016,2:3(Suppl)